News | September 07, 2021
Indian Pharmaceutical Market grew by 17.7 per cent in August
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
The segment delivered strong sales growth of 20% YoY
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Demand normalisation post the second wave contributed to the steady growth
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
